A Phase 3, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tegoprazan 25 mg for the Prevention of Peptic Ulcer Disease in Patients on Continuous Long-term Treatment With NSAIDs
Latest Information Update: 16 Jul 2023
Price :
$35 *
At a glance
- Drugs Lansoprazole (Primary) ; Tegoprazan (Primary)
- Indications Duodenal ulcer; Gastric ulcer; Peptic ulcer
- Focus Therapeutic Use
- Sponsors HK inno.N
- 25 Jan 2023 Planned End Date changed from 1 Jan 2023 to 1 Jul 2024.
- 25 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Jun 2024.
- 07 May 2021 Status changed from not yet recruiting to recruiting.